Clinical Trials Directory

Trials / Unknown

UnknownNCT04370197

Covid-19 Epidemic on Acute Stroke Management

Impact of th Covid-19 Epidemic on Acute Stroke Management

Status
Unknown
Phase
Study type
Observational
Enrollment
300 (estimated)
Sponsor
University Hospital, Strasbourg, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The Covid-19 pandemic is a pandemic of an emerging infectious disease, coronavirus 2019 (Covid-19), caused by the coronavirus SARS-CoV-2. It appears in November 2019 in the city of Wuhan, China, and spreads worldwide from February 2020. The first cases of infection in France were confirmed on 24 January 2020. As of April 14, 103,573 cases of infection were confirmed, 32,292 hospitalized cases, including 6,730 in intensive care, with 15,729 deaths recorded1. The most affected regions are Ile de France and the Grand Est (in particular the Haut-Rhin department). Containment of the entire French population was introduced on 17 March, with the aim of reducing the spread of the virus and relieving the burden on the health system, particularly the intensive care units. This unprecedented health crisis, as well as the social containment measures in themselves, has repercussions on other acute medical pthologies, not directly related to the viral infection. It appears that the number of patients treated for acute stroke has suddenly declined since the beginning of the epidemic. However, it is not clear whether it is the incidence of stroke that has declined or simply the proportion of patients presenting within the time frame that allows for treatment in the acute phase (by thrombolysis or thrombectomy).

Conditions

Timeline

Start date
2020-03-03
Primary completion
2020-04-30
Completion
2020-04-30
First posted
2020-04-30
Last updated
2020-04-30

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04370197. Inclusion in this directory is not an endorsement.